skip to Main Content

What is The International Liver CongressTM?

The International Liver CongressTM is the annual EASL meeting, and the flagship event in EASL’s educational calendar.

Every year in April, scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology and radiology and imaging come together from around the world to learn about the latest in liver research.

Specialists share recent data, present studies and findings, and discuss the hottest topics on liver disease. The annual Congress attracts around 10,000 delegates and 250 media representatives from all over the world making this a truly international networking opportunity!

The International Liver CongressTM 2019 will take place 10-14 April 2019 at the Reed Messe Wien Exhibition & Congress Center, Vienna, Austria.

ILC 2019 venue address:

Reed Messe Wien Exhibition & Congress Center
Trabrennstraße 7,
1020 Vienna,

Station Krieau
Congress Entrance: Foyer D

My location
Get Directions

Dicover the ILC 2018 Congress Report


The International Liver Congress (ILC) 2018, the 53rd annual meeting of the European Association for the Study of the Liver (EASL), was held  in Paris, France, and was attended by 9,669 delegates from 121 countries. The field of hepatology is undergoing dramatic changes, with a major increase in metabolic liver diseases and liver cancer worldwide, highly effective drugs to cure hepatitis C now available, and  multiple novel treatment concepts for rare liver diseases and hepatitis B emerging.

During the opening ceremony, the ILC 2018 Honorary President, Tilman Sauerbruch, reminded the audience of the huge clinical and scientific advances that have been made in hepatology during the course of his illustrious career. He highlighted that, for example, survival after the first liver transplantations performed by Thomas Starzl in 1963 was just 0–23 days, compared with 1-year survival rates of 85% now, 55 years later. In other areas in the same time period, all viral causes of hepatitis were identified. However, despite these real advances in  hepatology, many challenges remain…


Download the full ILC 2018 Congress Report

The ILC2018 Congress Report was supported by grants from: Abbvie, Alexion Pharma GmbH, Boehringer Ingelheim, Gilead Sciences Europe Ltd, MSD and Pfizer.